Mathew, Paul <br/><br/>
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.  [electronic resource] 

 -  Clinical genitourinary cancer  Sep 2006 
 - 144-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1558-7673 
<br/><br/><label>Standard No.: </label>10.3816/CGC.2006.n.031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bridged-Ring Compounds--adverse effects<br/>Disease Progression<br/>Estramustine--administration & dosage<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms, Hormone-Dependent--drug therapy<br/>Paclitaxel--administration & dosage<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--drug therapy<br/>Survival Rate<br/>Taxoids--adverse effects<br/>Thalidomide--administration & dosage<br/>Time Factors<br/>Treatment Outcome